Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Ticagrelor 90 mg tablets in healthy Thai volunteers under fasting conditions
TCTR20221017003Phase 1Unknown
- Sponsor
- Bio-innova
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in coronary arteriosclerosis, myocardial infarction (MI) and acute coronary syndrome (ACS) (2 arms), sponsored by Bio-innova. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on TCTR20221017003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221017003.